Introduction {#sec1-1}
============

Neuromyelitis optica (NMO) is classically described as optic neuritis and longitudinal extensive transverse myelitis, and is associated with other autoimmune disorders in 10--40% of patients (Takahashi et al., 2007; Gono et al., 2011). The diagnosis of NMO spectrum disorder (NMOSD) is greatly facilitated by screening for a specific biomarker for NMO: immunoglobulin G (IgG) antibodies targeting water channel protein aquaporin 4 (AQP4) in the astrocytic foot processes, which contributes to the formation of the blood brain barrier (Wingerchuk et al., 2007; Wang et al., 2014; Kleiter and Gold, 2016).

Despite a prevalence ranging between 1--3% in the general population, approximately 30% of primary Sjögren\'s syndrome (pSS) patients present with additional autoimmune diseases (Peri et al., 2012). Several studies have reported that organ-specific autoimmune diseases, such as thyroid diseases and myasthenia gravis, and non-organ-specific autoimmune diseases, such as systemic lupus erythematosus, pSS, rheumatoid arthritis, and undifferentiated connective tissue disease, are strongly associated with NMOSD (Takahashi et al., 2007; Pittock et al., 2008; Gono et al., 2011).

pSS is a chronic autoimmune disease of the exocrine glands characterized by focal lymphocytic infiltration and destruction of these glands. The diagnosis of pSS requires a set of rigorous clinical tests. The most widely accepted diagnostic standard is the European criteria of Vitali (Vitali et al., 2002). Sjögren\'s syndrome is more frequent in women, with a female-to-male ratio of 9:1, and peaks in patients in their mid-50s (Tzioufas et al., 2008). Central nervous system manifestations in pSS are diverse and span the entire neuroaxis. There is no consensus regarding the prevalence of central nervous system involvement in pSS. A few studies have attempted to address the relationship between pSS and NMOSD (Massara et al., 2010). However, the characteristics of different NMOSDs have not been sufficiently investigated. The aim of this study was to investigate the neurological, laboratory, and MRI features of NMOSD patients, with or without pSS, and their clinical outcomes.

Subjects and Methods {#sec1-2}
====================

Subjects {#sec2-1}
--------

We retrospectively studied 16 NMOSD patients who were diagnosed and admitted to the First Hospital of Jilin University of China between May 2010 and May 2014.

The following data were collected from the medical records: age at disease onset, age at diagnosis, age at first neurological manifestation, disease duration (calculated from time of disease onset to January 2014), radiological characteristics, laboratory investigations, and treatment. NMO was defined using the 2006 clinical diagnostic criteria (Wingerchuk et al., 2006). Other criteria included: (a) autoantibody analysis conducted, including anti-AQP4 antibody, extractable nuclear antigen, autoantibodies antinuclear (ANA) antibodies, and antineutrophil cytoplasmic antibodies; (b) availability of the following laboratory data: rheumatoid factors, immunoglobulins, complement C3 and C4, and thyroid hormones; and (c) MRI scan of the brain and spinal cord.

pSS was diagnosed using a set of rigorous clinical and immunologic criteria based on the most widely accepted European criteria of Vitali (Vitali et al., 2002). In addition, NMOSD was defined using the revised clinical diagnostic criteria of Wingerchuk et al. (2007). Owing to the complexity of symptoms, physicians paid special attention to atypical extraglandular symptoms in addition to the classical clinical evidence of xerophthalmia, xerostomia, and laboratory test results, suggesting a systemic autoimmune disease. At the time of pSS diagnosis, minor salivary gland biopsies showed lymphocytic infiltration in all pSS patients.

All patients were evaluated by neurologists/rheumatologists, and neurological manifestations were only attributed to pSS after excluding other causes. The patients were divided into two groups: one with ten NMOSD patients without pSS and the other with six NMOSD patients with pSS. The study was approved by the local Ethics Committee of First Hospital of Jilin University of China (Approval No. 2010-3). Written informed consent was obtained from the participants and their family members.

Laboratory analyses and MRI {#sec2-2}
---------------------------

Fasting venous blood and cerebrospinal fluid samples were collected from the participants during their visits to the hospital. The following laboratory tests were performed in all patients: serum IgG, complement C3 and C4, cryoglobulins, anti-AQP4, cerebrospinal fluid oligoclonal banding, rheumatoid factors, antinuclear, anti-Sjögren\'s-syndrome-related antigen A (SSA), anti-Sjögren\'s-syndrome-related antigen B (SSB), and antiphospholipid antibodies (Wang et al., 2014). A standard MRI examination was performed using a GE MR scanner at 1.5Tesla (GE, Boston, MA, USA), including brain, spinal cord, and enhancement scanning in all patients. Each patient underwent MRI at the time of the initial diagnosis, prior to corticosteroid or immunomodulatory treatment.

Statistical analysis {#sec2-3}
--------------------

Statistical analysis was performed using SPSS 17.1 (SPSS, Chicago, IL, USA). The differences between the groups (pSS *versus* without pSS) were analyzed using chi-square tests or Fisher\'s exact tests for qualitative data. One-way analysis of variance and the least significant difference tests were used to analyze quantitative data. All quantitative data are presented as the mean ± SD. A *P* value \< 0.05 was considered to be statistically significant.

Results {#sec1-3}
=======

Comparison of clinical manifestations and neurological findings between NMOSD patients with and without pSS {#sec2-4}
-----------------------------------------------------------------------------------------------------------

The cohort consisted of five (83%) females, one (17%) male (ratio of females to males, 5:1) in the NMOSD with pSS patient group and nine (90%) females, one (10%) male (ratio of females to males, 9:1) in the NMOSD without pSS patient group. Only one (17%) patient with pSS and two (20%) patients without pSS had visual impairment as the first manifestation of NMOSD. Spinal cord involvement was the first symptom in two (33%) patients with NMOSD and occurred in four (40%) patients without pSS. The demographic and first neurological involvements at onset were compared between NMOSD patients with and without pSS, and there was no significant difference. Nevertheless, the prevalences of xerostomia and xerophthalmia were significantly higher in NMOSD patients with pSS than in NMOSD patients without pSS (*P* \< 0.05; **[Table 1](#T1){ref-type="table"}**).

###### 

Demographic and clinical characteristics of NMOSD patients with or without pSS
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Comparison of laboratory analyses between NMOSD patients with and without pSS {#sec2-5}
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The laboratory findings of the patients are presented in **[Table 2](#T2){ref-type="table"}**. There were no significant differences in CSF or IgG index between NMOSD with and without pSS.

###### 

Laboratory findings of NMOSD patients with or without pSS
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Serum C-reactive protein levels were significantly higher in NMOSD patients with pSS compared with those without pSS (*P* \< 0.05). Moreover, ANA, anti-SSA/Ro antibodies, anti-SSB/La antibodies, and anti-Sm antibodies were significantly higher in NMOSD patients with pSS than those without pSS (*P* \< 0.05). Anti-AQP4 was detected in 67% (4/6) of NMOSD patients with pSS and in 60% (6/10) of NMOSD patients without pSS.

Comparison of the neuroimaging features between NMOSD patients with and without pSS {#sec2-6}
-----------------------------------------------------------------------------------

As shown in **[Table 3](#T3){ref-type="table"}**, more NMOSD patients without pSS had brain abnormalities than those with pSS (80% *versus* 17%, *P* \< 0.05). However, there were no statistical differences between the two groups in other MRI features. Segment lesions (\> 3 centrum) on spinal cord MRI scans were noted in 50% (5/10) of NMOSD patients without pSS and in 67% (4/6) of NMOSD patients with pSS. We also observed gray matter lesions in the basal ganglia of NMOSD patients with pSS. Corpus callosum lesions were rarely observed. In cases of acute myelopathy, we frequently observed an extended T2-weighted hyperintensity involving a large part of the cord (**[Figure 1](#F1){ref-type="fig"}**).

###### 

MRI findings of lesions in NMOSD patients with or without pSS
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![Brain and cervical cord MRI of a 74-year-old female patient with neuromyelitis optica spectrum disorder and primary Sjögren\'s syndrome.\
(A) Sagittal magnetic resonance T2-weighted images show a strip of hyperintensity in the cervical cord (C~3--7~). (B) Axial fluid-attenuated inversion recovery images show several small hyper-intensities in the white matter near both lateral ventricles in the brain. L: Left; A: anterior; P: posterior.](NRR-11-1633-g005){#F1}

Discussion {#sec1-4}
==========

NMO is an immune-mediated neurological disorder characterized by recurrent episodes of optic neuritis and longitudinally extensive transverse myelitis. A serum biomarker, anti-AQP4, has been specifically associated with NMOSD and is useful in early recognition of the disease and for predicting relapses. Other autoimmune disorders, both organ-specific and generalized, are observed in 20--30% of NMOSD cases (Wang et al., 2014). These disorders, which may become symptomatic before or after the development of NMOSD, are often diagnosed long after the diagnosis of NMOSD. Iyer et al. (2014) identified that pSS and systemic lupus erythematosus were the most common autoimmune disorders co-existing with NMOSD. Thus, central nervous system disorders such as NMOSD, and autoimmune diseases such as pSS may coexist for a long time prior to being diagnosed correctly. This poses a challenge for diagnosis and contributes to a high number of misdiagnosed cases in young female patients with neurological symptoms.

This study also showed the diversity of manifestations of NMOSD. Although most of the patients with neurological involvement were female, NMOSD patients with pSS or other autoimmune disorders have also been observed in males (Delalande et al., 2004). Neurological involvement precedes the diagnosis of pSS in 25--81% of patients (Gono et al., 2011). The optic nerve, spinal cord and brainstem are involved earliest in NMOSD patients. The most frequently observed clinical manifestations are optic atrophy, motor or sensory deficit, headache, dizziness, intractable hiccups, and nausea. The results of this study demonstrate that the initial neurological involvement at the onset and clinical manifestation with pSS were less frequent than in patients without pSS, although the difference was not statistically significant.

In a previous study, 47% of NMOSD patients had autoantibody markers of pSS (Jacob et al., 2013). Previous reports have shown that although autoantibodies in the serum (particularly ANA, anti-SSA/Ro antibodies, and anti-SSB/La antibodies in this study) can be found in all NMOSD subtypes, the titer varies in different subtypes. Antinuclear antibodies are common in NMOSD patients, especially in those with pSS (Pittock et al., 2008). NMO patients often show concomitant autoantibodies, for example, anti-SSA/Ro antibodies, which are frequently detectable in AQP4-seropositive patients (de Seze et al., 2002). Our observations are in line with these previous findings.

With the recent discovery of the anti-AQP4 antibody, which is considered to be specific for NMOSD, an overlap between patients with pSS and NMOSD has been noted (Massara et al., 2010). Anti-AQP4 antibody was detected in all patients in the present study. Previous studies have suggested that anti-AQP4 autoantibody plays a role in the pathogenesis of NMO: AQP4 expression is absent from NMOSD lesions, and titers of anti-AQP4 appear to correlate with disease activity (Jarius et al., 2008; Ramos-Casals et al., 2008). Autopsies of NMOSD spinal cord lesions have revealed immunoglobulin and complement deposits in the endothelial cell wall (Mandler., 1993). Thus, if optic neuritis, longitudinally extensive transverse myelitis, or multiple lesions are detected in the spinal cord and white matter of pSS patients, anti-AQP4 antibody should be screened for (Takahashi et al., 2007; Kahlenberg, 2011).

The pathophysiological mechanisms of the neurological involvement in pSS are still unclear. The diverse clinical features imply the possibility of distinct pathogenic pathways. In peripheral neuropathy, lymphocytic infiltration of the dorsal ganglia seems to be the main phenomenon involved (Iyer et al., 2014). Griffin et al. (1990) have also described T lymphocyte infiltration of the ganglia with neuronal degeneration. In multiple mononeuropathies, nerve biopsy often reveals vasculitis (Grant et al., 1997), which could explain the good efficacy of corticosteroids and immunosuppressive drugs in these cases. We have previously demonstrated a high concentration of cryoglobulin in sensory motor neuropathy, implying the possible pathophysiologic role of this protein (Hebbar et al., 1995). Many studies have suggested an ischemic mechanism of central nervous system complications in pSS (Alexander, 1993). Bakchine et al. (1991) supported another hypothesis regarding mononuclear cell infiltration in the central nervous system in a pathologic case. Additional mechanisms such as immunologically mediated vascular damage in the central nervous system, the action of anti-neuron antibodies (Mauch et al., 1994), or a direct role of anti-Ro/SSA antibodies, have also been suggested.

In summary, the clinical characteristics, laboratory investigation results, and MRI features are similar in NMOSD patients with or without pSS.
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